Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

f unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the sufficiency of Nile's available capital, timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are descr
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 The chemistry, taste, and health ... a new article published by the nonprofit American Botanical Council ... climate change and its effects on the phytochemical compounds in ... study conducted by Dr. Ahmed in the Yunnan ... and has implications for the future of medicinal botanicals. Dr. ...
(Date:9/15/2014)...  The second annual International Plasma Awareness Week ... initiative of the Plasma Protein Therapeutics Association ... designed to: , Raise global awareness about ... plasma donors in saving and improving lives , ... diseases Member companies are planning a ...
(Date:9/13/2014)... 2014 Boehringer Laboratories Inc., with a ... to announce the successful broadcast of a live surgery ... Claros, MD, FACS, FAMBS, and Maher El Chaar, MD, ... System. , This sleeve gastrectomy surgery was performed ... than four hundred surgeons from around the world during ...
(Date:9/12/2014)... Mountain View, CA (PRWEB) September 12, 2014 ... its fundraising campaign on Indiegogo. , The film, ... Stephen Hawking, Buzz Aldrin, Shimon Peres, Ashton Kutcher, Will.i.Am, ... changing the world and there’s only one university in ... it to help change the lives of a billion ...
Breaking Biology Technology:Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2
... Dec. 20 Northwest,Biotherapeutics, Inc. (OTC Bulletin ... ("NWBT") announced today that Lonza Group AG ... NWBT,s DCVax(R)-Brain,product and other NWBT DCVax(R) products ... DCVax(R) cancer vaccine products infringed,certain gene expression ...
... teens and adults, HIGHLANDS RANCH, Colo., Dec. 19 ... its treatment services to,include a detox program. The new ... adults, and the hospital has added several new physicians ... abuse and,mental illness)., Teen suicide rates nationally are ...
... PALO ALTO, Calif., Dec. 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... V. Barron, MD, FACC to its Board of Directors. ... Medical Officer at Genentech,where he leads the Development organization, ... Dr. Barron joined Genentech in 1996 as a clinical ...
Cached Biology Technology:Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 2Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 3Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 4Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3
(Date:9/15/2014)... an unprecedented evolution experiment scientists from GEOMAR Helmholtz ... Institute of Sea Fisheries have demonstrated for the ... algae of the world,s oceans, Emiliania huxleyi ... rising water temperatures. In their study, the researchers ... evolutionary adaptations to these two aspects of climate ...
(Date:9/15/2014)... Ebola virus outbreak in West Africa, which has claimed ... a deeper understanding of the molecular biology of the ... vaccines or antiviral drugs to treat or prevent Ebola ... Virginia (UVA), USA under the leadership of Dr ... structural biologist has obtained the crystal structure of ...
(Date:9/15/2014)... September 15, 2014 Schizophrenia is generally considered to ... many risk factors, both genetic and environmental, with other ... The normal path for brain development is determined by ... and a wide range of environmental factors. , However, ... populations are required in order to map the disturbances ...
Breaking Biology News(10 mins):Small algae with great potential 2Small algae with great potential 3Protein secrets of Ebola virus 2Brain Development in Schizophrenia Strays from the Normal Path 2
... AUSTIN, Texas , April 17, 2013 Vermillion, ... company focused on gynecologic cancers and women,s health, announced the ... with the U.S. Army Medical Research and Materiel Command ... titled, "Cost Reduction Using OVA1 in a Treatment Algorithm ...
... Recent developments in postharvest disease control will be highlighted at ... sponsored by the University of California, Riverside Extension ... run from 8 a.m. to 5 p.m. Tuesday, April 23, and ... Santa Barbara . This year,s conference will include a large ...
... Committee for the Asian hornet, the Vespa velutina ... Community (region), the Charter Provincial Councils, the Beekeeping sector ... aimed at controlling the Vespa velutina populations ... an invasive species from France that preys on bees ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4Conference to highlight latest in postharvest pest control 2
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
... Mouse monoclonal [F30 P7 D7 ... for all tested applications). ... conjugated to Ovalbumin, corresponding to amino ... Entrez Gene ID: ...
DAP12 Market Segment: Protein Kinases...
G-protein coupled purinergic receptor P2Y8...
Biology Products: